Pure client since 2008. Led branding and PR efforts to launch the company and continue to provide corporate and product PR services as the company prepares to commercialize its lead product, the novel PERT liprotamase. In July 2010, Eli Lilly announced definitive agreement to acquire Alnara, less than two years after the launch of the company.

Pure client since 2005. Integrated corporate communications services for the publicly traded ARIAD (NASDAQ: ARIA), a Cambridge, Massachusetts-based biotechnology company focused on cancer.

Pure client since 2007. Scope of work for AVEO (NASDAQ: AVEO) includes integrated corporate and product communications encompassing PR, IR and digital media.

Pure client since 2009. Supporting rebranding efforts in the U.S. and Europe of this external R&D unit within GSK, with the launch of a new website, event management, strategic communications counsel and media relations.

Pure client since 2008. Services include strategic positioning and media outreach campaign for the company and its noninvasive EndoBarrier^™ technology, designed to modify metabolic pathways by lining a portion of the gastrointestinal tract, for the treatment of obesity and type 2 diabetes.

Pure client since 2007. Leading corporate communications efforts for the publicly traded (NASDAQ: INFI) company with a mission to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

Pure client since 2008. Spearheading corporate and product focused communication strategies for the worldwide leader in medical imaging, with headquarters in North Billerica, Massachusetts, and nearly 700 employees worldwide with offices in Puerto Rico, Canada, and Australia.

Pure client since 2009. Managing media relations campaign for the company, based in Israel and the U.S., and its medical device portfolio, which includes the first major advance in tissue reconnection for gastrointestinal surgery in more than 30 years.

Pure client since 2006. Efforts include multi-faceted communications programming and counsel spanning preclinical and clinical product development, business development and patient advocacy initiatives for this New Jersey-based biotech company focused on post-transcriptional control/mRNAi drug discovery.

Pure client since 2008. Leading a multi-pronged strategic media relations, investor relations and digital communications program to drive awareness as the Bothell, Washington company leverages promising science in visual cycle modulation to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.